Chemotherapy: cyclophosphamide (CYC)

Phase 1

Chemotherapy: cyclophosphamide (CYC) is one of 3 therapeutic programs targeting Progressive Multiple Sclerosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Progressive Multiple SclerosisActive, not recruiting

Progressive Multiple SclerosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Progressive Multiple Sclerosis

#DrugCompanyPhaseTrials

Ocrevus

Roche

Phase 2

1 2

Rapcabtagene Autoleucel

Novartis

Preclinical

1 3

Chemotherapy: cyclophosphamide (CYC)

BBruce Cree

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Progressive Multiple Sclerosis

NCT06451159

Clinical

Trials by Indication[1]

Progressive Multiple Sclerosis1 trial

Phase 1, Open-Label, Single Center Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis

Active, not recruiting·BBruce Cree·Phase 1·NCT06451159·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Chemotherapy: cyclophosphamide (CYC). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Chemotherapy: cyclophosphamide (CYC). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Bruce Cree company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: BBruce Cree

Chemotherapy: cyclophosphamide (CYC)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Progressive Multiple Sclerosis1 trial

References

Drug Info

Quick Facts

Related News